NCT03380039View on ClinicalTrials.gov

Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma

NAUnknownINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 13, 2017

Primary Completion Date

July 2, 2020

Study Completion Date

July 2, 2023

Conditions
Refractory or Relapsed Multiple Myeloma
Interventions
GENETIC

CAR-BCMA T cells

"Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied."

DRUG

Fludarabine

Fludarabine is used for lymphodepletion.

DRUG

Cyclophosphamide

Cyclophosphamide is used for lymphodepletion.

Trial Locations (1)

200092

Xin Hua Hospital of Shanghai Jiao Tong University of Medicine, Shanghai

Sponsors
All Listed Sponsors
collaborator

CARsgen Therapeutics Co., Ltd.

INDUSTRY

lead

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER